Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV

Conclusion: Dolutegravir exposure was marginally lower in participants with obesity, but this is not clinically significant. Our findings suggest that there is no need to dose adjust dolutegravir in people with obesity.
Source: Southern African Journal of HIV Medicine - Category: African Health Authors: Source Type: research